RBA still seen hiking next week as energy shock starts to bite.
The market is materially undervaluing the investment company's shares, says chair.
But investors have punished the company for its gross margin outlook.
The company is selling a $30m property as part of its strategy to cut costs.
The ASX-listed company is guiding ebitda break-even for the first time in 2024.
Supie chair and major shareholder come out swinging in defence of CEO and founder Sarah Balle as company hits capital roadblock.
Listed insurer talks up resilience as catastrophic weather dampens profit.
The cancer diagnostics company still has overhang of decision on Medicare coverage in the US.
The NZX-listed hospitality operator has never paid one out to shareholders.
The company has put emphasis on cash flow reporting but it’s not transparent enough for one analyst.
